company background image
002349 logo

Jinghua Pharmaceutical Group SZSE:002349 Stock Report

Last Price

CN¥6.73

Market Cap

CN¥5.5b

7D

1.1%

1Y

-24.5%

Updated

13 Jul, 2024

Data

Company Financials

Jinghua Pharmaceutical Group Co., Ltd.

SZSE:002349 Stock Report

Market Cap: CN¥5.5b

002349 Stock Overview

Engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China.

002349 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends4/6

Jinghua Pharmaceutical Group Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jinghua Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥6.73
52 Week HighCN¥10.88
52 Week LowCN¥5.88
Beta0.033
11 Month Change-5.34%
3 Month Change-10.98%
1 Year Change-24.47%
33 Year Change31.45%
5 Year Change18.28%
Change since IPO100.70%

Recent News & Updates

Jinghua Pharmaceutical Group's (SZSE:002349) Upcoming Dividend Will Be Larger Than Last Year's

Jun 07
Jinghua Pharmaceutical Group's (SZSE:002349) Upcoming Dividend Will Be Larger Than Last Year's

Recent updates

Jinghua Pharmaceutical Group's (SZSE:002349) Upcoming Dividend Will Be Larger Than Last Year's

Jun 07
Jinghua Pharmaceutical Group's (SZSE:002349) Upcoming Dividend Will Be Larger Than Last Year's

Shareholder Returns

002349CN PharmaceuticalsCN Market
7D1.1%-0.6%1.2%
1Y-24.5%-15.3%-18.5%

Return vs Industry: 002349 underperformed the CN Pharmaceuticals industry which returned -15.3% over the past year.

Return vs Market: 002349 underperformed the CN Market which returned -18.5% over the past year.

Price Volatility

Is 002349's price volatile compared to industry and market?
002349 volatility
002349 Average Weekly Movement4.0%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.0%
10% least volatile stocks in CN Market4.3%

Stable Share Price: 002349 has not had significant price volatility in the past 3 months.

Volatility Over Time: 002349's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19571,493Yunzhong Zhouwww.jinghuapharm.com

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd.

Jinghua Pharmaceutical Group Co., Ltd. Fundamentals Summary

How do Jinghua Pharmaceutical Group's earnings and revenue compare to its market cap?
002349 fundamental statistics
Market capCN¥5.48b
Earnings (TTM)CN¥231.11m
Revenue (TTM)CN¥1.46b

23.7x

P/E Ratio

3.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
002349 income statement (TTM)
RevenueCN¥1.46b
Cost of RevenueCN¥755.45m
Gross ProfitCN¥707.07m
Other ExpensesCN¥475.96m
EarningsCN¥231.11m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 28, 2024

Earnings per share (EPS)0.28
Gross Margin48.35%
Net Profit Margin15.80%
Debt/Equity Ratio0.7%

How did 002349 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

32%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.